Application of membrane-source-opening beverage in preparation of acute lung injury resisting medicine

Abstract

The invention provides application of a membrane-source-opening beverage in preparation of an acute lung injury resisting medicine. The membrane-source-opening beverage is utilized for preparing the acute lung injury resisting medicine. The method comprises the steps that the membrane-source-opening beverage is placed in water for backflow, and an extracting solution is obtained and concentrated to obtain a membrane-source-opening beverage aqueous extract or a total extract; after ethyl alcohol is added into the total extract, standing and suction filtration are performed, the obtained filtrate is concentrated to obtain supernate of membrane-source-opening beverage water extracting alcohol precipitation. By means of the membrane-source-opening beverage, symptoms of pulmonary edema in mice can be relieved, the content of nitric oxide and protein in bronchoalveolar lavage fluid is lowered, the content of the tumor necrosis factors -alpha (TNF-alpha), interleukin-6(IL-6) and interleukin-1beta(IL-1beta) is lowered, the complement C3, C3c, C5a level in blood serum is lowered, the protective effect is achieved on the lung tissue, lung cells and blood capillaries of mice, and the complement precipitation in the lung tissue is relieved.

Description

technical field [0001] The invention relates to the application of Dayuan decoction in the preparation of anti-acute lung injury medicine. Background technique [0002] Acute lung injury (acutelunginjury, ALI) is based on diffuse lung cell injury, pulmonary edema and pulmonary inflammatory cell infiltration caused by pulmonary vascular injury are its pathological features, and the main clinical manifestations are severe hypoxemia, diffuse Acute respiratory distress syndrome (ARDS) will eventually develop in some patients, causing irreversible acute respiratory failure and multiple organ dysfunction, with a mortality rate as high as 30-40%; the pathogenesis of ALI is complex The risk factors for ALI can be direct damage from the lungs, or indirect damage to the lungs from extrapulmonary factors through systemic inflammatory responses (see: BaffertF, LeT, ThurstonG, et al.Angiopoietin-1decreasesplasmaleakagebyreducingnumberandsizeofendothelialgapsinvenules. 290(1):H107-H118;W...

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment plan for ALI is generally recognized at home and abroad: (1) remove the cause; (2) on the basis of active treatment of the primary disease, mechanical ventilation (Mechanical ventilation, MV) should be used as soon as possible to correct hypoxia and improve tissue oxygen supply; MV is ALI One of the classic treatment methods can correct refractory hypoxia, prevent alveolar collapse, resist pulmonary edema, improve gas exchange, reduce spontaneous breathing work, and prevent respiratory muscle fatigue, but it can only maintain the body's physiological breathing and cannot completely solve the problem All problems of ALI; (3) drug treatment; clinically, adrenal glucocorticoids, glucocorticoids, cyclophosphamide, methotrexate, etc. are widely used in the treatment of acute lung injury, which can reduce capillary exudation and inhibit the formation of pulmonary fibrosis , so that lung function can be improved rapidly; but immunosuppressants such as glucocorticoids have poor selectivity for acute lung injury, and long-term application will produce various complications and side effects (see: Yang Yongtao, Wang Zhengqing

Images